Stem Cells Market Size to Extend by USD 49.26 Billion in 2034

Stem Cells Market Size, Shares and Recent Developments

The global stem cells market size was estimated at US$ 14.92 billion in 2023 and is projected to grow to US$ 49.26 billion by 2034, rising at a compound annual growth rate (CAGR) of 11.47% from 2023 to 2034. Growing research and development in different stem cells for therapeutic purposes is driving the market’s growth.

Unlock Infinite Advantages: Subscribe to Annual Membership

Major Key Insights of the Stem Cells Market

• By region, North America dominated the stem cells market share by 44.2% in 2023.
• By region, Asia Pacific is expected to grow at the fastest rate during the forecast period.
• By product, the adult stem cells segment held the largest share of the market in 2023.
• By product, the induced pluripotent stem cells segment is expected to grow at the fastest rate during the forecast period.
• By application, the regenerative medicine segment dominated the stem cells market in 2023.
• By application, the drug discovery and development segment is anticipated to grow at the fastest rate during the forecast period.
• By technology, the cell acquisition segment held the dominant share of the market in 2023.
• By therapy, the allogenic segment dominated the market in 2023 and is estimated to show the fastest growth during the forecast period.
• By end-use, the pharmaceutical & biotechnology companies segment held the largest stem cells market share and is anticipated to hold the dominant position during the forecast period.

Stem Cells Market: Diagnostics & Therapeutics

The ability of stem cells to self-renew is amazing. In the early stages of life and growth, they can differentiate into a wide variety of cell types in the body. Researchers have investigated numerous varieties of stem cells. Stem cells can be used by researchers to understand human biology and create new treatments. Improved comprehension of the genetic and molecular cues that control stem cell proliferation, specialization, and differentiation might provide insights into the etiology of disorders and provide novel therapeutic approaches.

How can AI Improve the Stem Cells Market?

The state of regenerative medicine is being advanced by stem cell treatment, but up until now, scientists and medical professionals have had to meticulously assess the quality of each stem cell by closely examining it under a microscope. Using the capabilities of artificial intelligence (AI), Japanese researchers have now discovered a technique to accelerate this procedure. Tokyo Medical and Dental University (TMDU) researchers revealed in a paper published in February in Stem Cells that their artificial intelligence (AI) system, named DeepACT, can detect healthy, productive skin stem cells with the same accuracy as a person.

Instance,

• In April 2024, the main investigator of a Northeastern research study on the automation and production of bio-drugs, MIE Assistant Professor Wei Xie, described the role artificial intelligence (AI) may play in efficient cell culture. Models for forecasting mechanisms in single and cluster cells are put out in two newly released publications by Xie and her co-authors.

Top Companies in the Stem Cells Market

• STEMCELL Technologies Inc.
• Mayo Clinic
• CellGenix GmbH
• Merck KGaA
• Takara Bio
• PromoCell GmbH
• Cellartis AB
• AcceGen
• ATCC
• Lonza
• Bio-Techne
• Cell Applications, Inc.
• Thermo Fisher Scientific, Inc.

Innovation by Mayo Clinic in the Stem Cells Market

Contribution by STEMCELL Technologies in the Stem Cells Market

SCs In Bone Marrow Transplantation Drives the Stem Cells Market

Right now, bone marrow transplantation is the most widely utilized stem cell-based treatment. The first stem cells to be identified and employed in a clinical setting were blood-forming stem cells found in the bone marrow. Thousands of patients worldwide who have been afflicted with blood malignancies, including leukemia, have benefited from this life-saving procedure. Research indicates that bone marrow transplants may be helpful in treating autoimmune illnesses and improving organ tolerance, in addition to their present usage in cancer therapies.

For instance,

• In August 2024, after just 18 months in operation, the bone marrow transplant unit at Kidwai Memorial Institute of Oncology (KMIO), the state's most renowned cancer hospital, is getting close to completing a century of treatments. Since its official opening, the facility has successfully performed 92 bone marrow transplants, and it can now handle up to 15 patients at once, as opposed to only two.

Ethical Issues Restraint the Stem Cells Market

Additionally, there are strong ethical and political debates around human stem cell (hSC) research. The donation of a frozen embryo raises a number of ethical issues, such as the donor's informed permission, the consent of the gamete donors who assisted in the production of the embryo, and the privacy of donor data.

Diabetes Treatment Can Revolutionize the Stem Cells Research

Diabetes is becoming more and more common, endangering human health and placing a heavy strain on healthcare systems worldwide. By regenerating insulin production and replacing damaged pancreatic beta cells, stem cell therapy has the potential to completely transform the management of diabetes. Researchers are investigating pluripotent stem cells as a potential tool for producing functioning beta cells in the lab and transplanting them into type 1 diabetic patients. This strategy might enhance blood sugar management and do away with the need for insulin injections, thereby improving the lives of individuals who are impacted by this illness.

The Adult Stem Cells (ASCs) Segment Dominated In 2023

By product, the adult stem cells (ASCs) segment held the largest share of the stem cells market in 2023. All fully grown tissues contain adult stem cells, which contribute to the upkeep and development of these tissues over the course of their lives. Adult stem cells are the best and most secure stem cells to use for therapeutic purposes. Stem cell treatment is widely utilized in clinics to treat hematological malignancies. The use of adult stem cells has led to the development of novel techniques in recent years for repairing damaged cartilage.

For instance,

• In February 2024, using a ground-breaking method to unlock the therapeutic potential of adult mesenchymal stem cells (MSCs), the University of Liverpool founded a new spin-out firm called TrophiCell. The method by which MSCs emit substances that encourage healing and lessen inflammation in long-term illnesses like osteoarthritis and liver disease is known as "trophic repair," which TrophiCell optimizes.

Fastest Growing: The Induced Pluripotent Stem Cells (iPSCs) Segment

By product, the induced pluripotent stem cells (iPSCs) segment is expected to grow at the fastest rate in the stem cells market during the forecast period. Regenerative medicine has significant potential to develop with the use of induced pluripotent stem cell (iPSC) technology, which has revolutionized in vitro research. iPSCs are highly expandable, accessible to genetic modification, and capable of differentiating into the majority of somatic cell types. iPSCs have been widely used to create cell treatments, simulate human development and illnesses, and conduct drug screening.

For instance,

• In March 2024, the de-extinction startup Colossal Biosciences' team of bioengineers revealed that they have generated induced pluripotent stem cells, or iPSCs, from parts of elephant skin. The team is still working on a manuscript that will detail their accomplishments; when it is finished, it will be uploaded to the bioRxiv preprint service, media representatives stated.

The Regenerative Medicine Segment Dominated in 2023

By application, the regenerative medicine segment dominated the stem cells market in 2023. The newest and most developing area of medicine is called "regenerative medicine," and it treats patients with chronic illnesses or catastrophic injuries by functionally restoring their tissues or organs. The groundwork for cell-based treatments for illnesses that traditional medications are unable to treat has been established by the astounding advancements in stem cell research.

Fastest Growing: The Drug Discovery & Development Segment

By application, the drug discovery & development segment is anticipated to grow at the fastest rate in the stem cells market during the forecast period. The possibility of using stem cells to develop more effective medications to treat human disease is only one of the numerous reasons for interest in this field. The main idea is that stem cells can open up new avenues for research into the pathophysiological causes of disease, clinical trial patient selection, drug lead screening, and effectiveness and safety testing of potential drugs.

For instance,

• In March 2024, Gladstone Institutes has led the way in stem cell research for more than ten years. And now, with the help of $4 million funding from the California Institute for Regenerative Medicine, Gladstone is going to create a center for CRISPR drug screening and stem cell disease modeling, significantly enhancing its capabilities.

The Cell Acquisition Segment Held the Largest Share In 2023

By technology, the cell acquisition segment held the dominant share of the stem cells market in 2023. The most popular method for obtaining stem cells is to take out blood from the patient, extract the stem cells, and then put the blood back into the patient. Before, bone marrow was the primary source of blood stem cells, and this is where they formed. Stem cells are removed from the circulation directly these days. A peripheral blood stem cell transplant is the second technique, while a bone marrow transplant is the first.

The Allogenic Segment Dominated the Market in 2023

By therapy, the allogenic segment dominated the stem cells market in 2023 and is estimated to show the fastest growth in the market during the forecast period. For "off-the-shelf" supply models, which are crucial in emergency medical circumstances, allogeneic techniques are especially well-suited. By using donor cells, these treatments enable the quick and easy preservation of medical supplies for the treatment of several patients. Time and resources are saved since this eliminates the need for customized cell preparation and retrieval. In addition to being more accessible and perhaps resulting in reduced manufacturing and patient expenses, allogeneic stem cell therapies can also scale more easily than autologous treatments.

For instance,

• In March 2024, Getinge and CellRev, a bioprocessing business, teamed together to develop Livit ACE, a continuous cell processing platform (Adherent Cell Expansion). The remedy, which goes on sale today, represents a manufacturing breakthrough for allogeneic cell therapy.

The Pharmaceutical & Biotechnology Companies Segment Dominated

By end-use, the pharmaceutical & biotechnology companies segment held the largest stem cells market share and is anticipated to hold the dominant position during the forecast period. Companies in the biotechnology and pharmaceutical industries have recently shown a greater interest in stem cell biology. Since the majority of large pharmaceutical firms employ adult or embryonic stem cells for internal drug development programs, the usage of stem cells as research tools has increased. The knowledge gained from external collaborations with academic institutions or biotech firms frequently strengthens these internal initiatives. One of the main advantages that the pharmaceutical industry will contribute to the field of regenerative medicine is its extensive experience forming solid collaborations with clinical institutions and international regulatory authorities over many years.

For instance

• In July 2024, in order to create a novel cartilage organoid cell therapy derived from pluripotent stem cell*1, Astellas Pharma Inc., Graduate School of Medicine / Faculty of Medicine, Osaka University, and Universal Cells have joined forces in research. This collaboration aims to treat intervertebral disc degenerative disease.

R&D in Healthcare Promotes North America’s Dominance

North America dominated the stem cells market share by 44.2% in 2023. Because there are so many significant market participants in North America, the region leads the global market. The market for stem cell therapies in this area is also being driven by government regulations, an advanced healthcare infrastructure, potential reimbursement, and growing awareness of stem cell therapies among the region's major populations. The regional market for stem cell therapy is attracting investors primarily because of the increased research and development efforts aimed at creating cutting-edge treatments and providing improved care to patients with life-threatening illnesses and medical professionals.

The U.S. holds the largest share of the stem cells market due to the presence of key market players and various research conducted by government bodies like NIH. With time, the NIH has invested in various stem cell research, which increases and promotes the usage of stem cells in various disease diagnoses and treatment development.

Government Support Promotes Market Growth in Asia Pacific

By region, Asia Pacific is expected to grow at the fastest rate during the forecast period. Because of its large patient population and strong product pipelines for stem cell-based therapies, the Asia Pacific area is expected to develop significantly. The market for stem cells is expected to grow significantly because of the rising prevalence of diseases, including diabetes, cancer, and neurological issues. In addition, government funding targeted at accelerating stem cell research supports the region's growth.

For instance,

• In February 2022, the Indian government set up state-of-the-art stem cell research facilities at 40 esteemed academic and medical research centers. In addition, the government has given the Indian Council of Medical Research (ICMR) US$ 80 million for a variety of research projects throughout the last three years.

Recent Developments in the Stem Cells Market

• In April 2024, future therapeutics and regenerative medicine can benefit from the mass production of pluripotent stem cells thanks to a novel paradigm. According to new research by experts at Northeastern University, artificial intelligence may be used to produce pluripotent stem cells on a massive scale. These cells might be used to cure diseases like cancer, Parkinson's disease, or Alzheimer's, as well as to repair spinal cords and slow down the aging process.
• In June 2023, bringing together scientists, legal academics, bioethics experts, and representatives from key funders and regulators of this research, Cambridge Reproduction is the project leader for Governance of Stem Cell-Based Embryo Models (G-SCBEM). Three-dimensional constructs that replicate certain elements of embryonic development are known as stem cell-based embryo models or SCBEMs. These crucial early developmental periods, which are often closed off to researchers, may be better understood with the help of SCBEMs.

Segments Covered in the Report

By Product

• Adult Stem Cells (ASCs)
  • Hematopoietic
  • Mesenchymal
  • Neural
  • Epithelial/Skin
  • Others
• Induced Pluripotent Stem Cells (iPSCs)
• Human Embryonic Stem Cells (HESCs)
• Very Small Embryonic Like Stem Cells

By Application

• Regenerative Medicine
  • Neurology
  • Orthopedics
  • Oncology
  • Hematology
  • Cardiovascular & Myocardial Infraction
  • Injuries
  • Diabetes
  • Liver Disorder
  • Incontinence
  • Others
• Drug Discovery & Development

By Technology

• Cell Acquisition
  • Bone Marrow Harvest
  • Umbilical Blood Cord
  • Apheresis
• Cell Production
  • Therapeutic Cloning
  • In-vitro Fertilization
• Cell Culture
  • Isolation
  • Cryopreservation
  • Expansion & Sub-Culture

By Therapy

• Allogenic
• Autologous

By End-use

• Pharmaceutical & Biotechnology Companies
• Hospitals & Cell Banks
• Academic & Research Institutes

By Region

• North America
  • U.S.
  • Canada
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Thailands
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Sweden
  • Denmark
  • Norway
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • UAE
  • Saudi Arabia
  • Kuwait